The pharmaceutical company, Mylan, says it will make a generic version of its EpiPen available, after criticism mounted over the increased price of its injectable medicine. 

The company says its U.S. subsidiary will put out a generic version of the EpiPen that will have a list price of $300 for a two-pack. It will be available in both 0.15 mg and 0.30 mg strengths.

Mylan N.V. said that it anticipates having the generic versions available in the next several weeks. It will continue to market and distribute its $608 branded EpiPen.

Mylan also said that it will keep in place the $200 savings card for the branded EpiPen and the revised patient assistance program that it announced last week.

Minnesota U.S. Senator, Amy Klobuchar made a statement about the company's launch of the generic EpiPen after last week she called for the Food and Drug Administration to answer questions about its approval process and their steps for alternatives to the EpiPen.

"The launch of a generic version of EpiPen is a step forward in addressing the dramatic price increase of the lifesaving medication. While I appreciate efforts to make the medication more accessible and affordable, today's action illustrates the need for a lasting solution that promotes competition and ensures the people have access to the medications they need at a price they can afford," Klobuchar said in a statement Monday. "We need to pass my bills that will increase drug industry competition and lead to lower prices for consumers on prescription drugs and I call on pharmaceutical companies to stop opposing these common sense measures. I also continue my call for the [Federal Trade Commission] investigation into this and other pharmaceutical pricing issues and I continue to seek answers to our questions to the FDA about its approval process and other steps for alternatives to the EpiPen."

Klobuchar introduced the Medicare Prescription Drug Price Negotiation Act of 2015, that would empower Medicare to negotiate for the pest possible price of prescription medication. Current law only allows for bargaining by pharmaceutical companies and bans Medicare from doing so.